@article{5ff5beaac96147d8ad3ddf1276a28aa7,
title = "Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial",
abstract = "We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Espa{\~n}ol de Linfomas/Transplante de M{\'e}dula {\'O}sea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.",
keywords = "clinical trials, diffuse large B-cell lymphoma, international prognostic index, rituximab",
author = "Mary Gleeson and Nicholas Counsell and David Cunningham and Anthony Lawrie and Laura Clifton-Hadley and Eliza Hawkes and Andrew McMillan and Ardeshna, {Kirit M.} and Cathy Burton and Nick Chadwick and Joanna Gambell and Paul Smith and Paul Mouncey and Christopher Pocock and John Radford and John Davies and Deborah Turner and Anton Kruger and Peter Johnson and David Linch",
note = "Funding Information: David Cunningham has received research funding from Amgen, Astra Zeneca, Bayer, Celgene, Medimmune, Merrimack, Merck Serono and Sanofi. Eliza Hawkes has received research funding from Astra Zeneca, Celgene, Merck KgA, BMS and Merck Sharpe and Dohme, honoraria for advisory boards or educational events from Roche, Takeda, BMS, Janssen, Celgene and travel expenses from Takeda and Bristol‐Myers Squibb. Kirit M. Ardeshna has received research funding, conference expenses and honoraria for attending or chairing advisory boards from Roche. Peter Johnson has received research funding from Janssen and Epizyme. All other authors declare that they have no conflicts of interest to report. Funding Information: Cancer Research UK provided endorsement and funding and the National Health Service (NHS) provided funding to the National Institute for Health Research (NIHR) Biomedical Research Centres at both University College London and the Royal Marsden Hospital/Institute of Cancer Research, London, UK. Chugai Pharmaceuticals provided an educational grant and lenograstim for the R-CHOP 14 vs. 21 trial. Publisher Copyright: {\textcopyright} 2020 British Society for Haematology and John Wiley & Sons Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = mar,
day = "16",
doi = "10.1111/bjh.16691",
language = "English",
volume = "192",
pages = "1015--1019",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons Ltd",
number = "6",
}
